Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer

NCT00250835 is registered in ClinicalTrials.gov with New Mexico Cancer Research Alliance as lead sponsor.

NCT NCT00250835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00250835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Lead sponsor
New Mexico Cancer Research Alliance
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2005
Completion date
May 31, 2015
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer